Featured In: Medical Electronics
FDA MedWatch | Friday, November 20, 2009
|
|
Double-click any word to search
Highlight any phrase & click HotSearch
|
FDA is reviewing preliminary data from a recent study suggesting
that patients using sibutramine have a higher number of
cardiovascular events (heart attack, stroke, resuscitated cardiac
arrest, or death) than patients using a placebo.
SOURCE
